CAR-T Therapy for T-lineage Leukemia:Progress,Dilemmas,and Way Forward

VernacularTitle:T系白血病的CAR-T治疗:进展、困境和未来出路
Author: Yajing HAN ¹ ; Liping ZHAO ; Kaiting TANG ; Qing NIU ; Jing PAN ; Xiaoming FENG
Author Information

1. 300020 天津,中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室;301600 天津,天津医学健康研究院
Keywords: Cellular immunotherapy; Chimeric antigen receptor T-cell thera-py; T-cell acute lymphoblastic leukemia
From: Cancer Research on Prevention and Treatment 2024;51(8):648-654
CountryChina
Language:Chinese
Abstract: Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies.Chimeric antigen receptor(CAR)T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical results in the treatment of B-lineage hematological malignancies.However,CAR T-cell therapy has some limitations in the treatment of T-cell acute lymphoblastic leukemia because of the presence of CAR T-cell fratricide,tumor cell contamination,T-cell aplasia,and other clinically relevant problems.Therefore,the current major challenge is overcoming the existing bottlenecks to optimize CAR-T therapy and improve its efficacy against T-ALL while improving the prognosis of patients.